Daily Archives: September 28, 2018

Therachon’s Rare Genetic Diseases Program Gets $60 Million Boost

Swiss-based biotechnology firm, Therachon, has closed $60 million round of funding, which will advance its achondroplasia program toward a drug trial, with treatments expected sometime in 2019. Novo Holdings led a cast of existing and new investors in the funding round. The financiers were Cowen Healthcare Investments, Pfizer Ventures, and funds managed by Tekla Capital Management LLC and the returning ...

Read More »